

25 May 2021

## Anticipated acquisition by AstraZeneca plc, of Alexion Pharmaceuticals, Inc

## Notice under section 96(2A) of the Enterprise Act 2002 (the Act) published pursuant to section 107(1)(i) of the Act

The Competition and Markets Authority (CMA) hereby gives notice pursuant to section 96(2A) of the Act that the merger notice provided by AstraZeneca plc in relation to the anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc (the **Merger**) meets the requirements of section 96(2) of the Act.

The initial period defined in section 34ZA(3) of the Act in relation to the Merger will therefore commence on the first working day after the date of this notice, ie on 26 May 2021. The deadline for the CMA to announce its decision whether to refer the Merger for a Phase 2 investigation is therefore 21 July 2021.